



Orthofix International Receives ACHC Accreditation

BOSTON, Apr 06, 2009 (BUSINESS WIRE) -- Orthofix International N.V. (NASDAQ: OFIX) (the Company) today announced that its subsidiary, Orthofix Inc., has been awarded accreditation status by the Accreditation Commission for Health Care, Inc., (ACHC) for the provision of Durable Medical, Prosthetics, Orthotics and Supplies (DMEPOS) services.

ACHC is a national not-for-profit corporation that was developed by home care and community-based providers to help companies improve business operations and the quality of patient care. The organization provides accreditation programs for various providers, including home health and hospice agencies, home infusion companies, home care aides, specialty pharmacies and home medical suppliers. Referring to the value of accreditation, ACHC President Tom Cesar indicated "The survey process leads an organization to examine its policies and practices continually to clarify its strengths and improve any weaknesses."

Accreditation is a voluntary activity where healthcare organizations submit their internal policies, processes and patient care delivery systems for peer review against national standards. By attaining accreditation, Orthofix Inc. has demonstrated its commitment to maintain a higher level of competency and strive for excellence in its products, services, and customer satisfaction.

"Orthofix Inc. is committed to quality product development and customer service as demonstrated by the ACHC accreditation as well as our history of meeting ISO 13485 standards," said Alan Milinazzo, President and CEO of Orthofix International. "We are proud to have achieved this very important accreditation, which is a testament to the professionalism and quality of work demonstrated by all our employees at Orthofix Inc."

About Orthofix

Orthofix International, N.V., a global medical device company, offers a broad line of minimally invasive surgical, and non-surgical, products for the spine, orthopedic, and sports medicine market sectors that address the lifelong bone-and-joint health needs of patients of all ages-helping them achieve a more active and mobile lifestyle. Orthofix's products are widely distributed around the world to orthopedic surgeons and patients via Orthofix's sales representatives and its subsidiaries, including BREG, Inc. and Blackstone Medical, Inc., and via partnerships with other leading orthopedic product companies. In addition, Orthofix is collaborating in R&D partnerships with leading medical institutions such as the Orthopedic Research and Education Foundation, Rutgers University, Texas Scottish Rite Hospital for Children and National Osteoporosis Institute. For more information about Orthofix, please visit www.orthofix.com.

Forward-Looking Statements

This communication contains certain forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of Orthofix and its subsidiaries and are based on management's current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements.

Factors that could cause or contribute to such differences may include, but are not limited to, risks relating to the expected sales of its products, including recently launched products, unanticipated expenditures, changing relationships with customers, suppliers and strategic partners, risks relating to the protection of intellectual property, changes to the reimbursement policies of third parties, changes to and interpretation of governmental regulation of medical devices, the impact of competitive products, changes to the competitive environment, the acceptance of new products in the market, conditions of the orthopedic industry and the economy, corporate development and market development activities, including acquisitions or divestitures, unexpected costs or operating unit performance related to recent acquisitions and other factors described in our annual report on Form 10-K and other periodic reports filed by the Company with the Securities and Exchange Commission.

SOURCE: Orthofix International N.V.

Orthofix International N.V.
Dan Yarbrough, 617-912-2903
Vice President of Investor Relations

danyarbrough@orthofix.com

Copyright Business Wire 2009